

Award Number: W81XWH-11-1-0009

TITLE: Studying the Roles of GRK2-Mediated Smad2/3 Phosphorylation as a Negative Feedback Mechanism of TGF-Beta Signaling and a Target of Breast Cancer Therapeutics

PRINCIPAL INVESTIGATOR: Jimin Guo

CONTRACTING ORGANIZATION: McGill University  
Montreal QC H3A2T5 CANADA

REPORT DATE: January 2014

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

| <b>REPORT DOCUMENTATION PAGE</b>  |                         |   | <i>Form Approved</i><br><i>OMB No. 0704-0188</i> |  |   |
|---|-------------------------|---|--|--|---|
| Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>   |                         |   |  |  |   |
| <b>1. REPORT DATE</b><br>January-2014   |                         | <b>2. REPORT TYPE</b><br>Annual Summary |  | <b>3. DATES COVERED</b><br>1 November 2010 - 31 October 2013 |   |
| <b>4. TITLE AND SUBTITLE</b><br>Studying the Roles of GRK2-Mediated Smad2/3 Phosphorylation as a Negative Feedback Mechanism of TGF-Beta Signaling and a Target of Breast Cancer Therapeutics   |                         |   | <b>5a. CONTRACT NUMBER</b>                       |  |   |
|   |                         |   | <b>5b. GRANT NUMBER</b><br>W81XWH-11-1-0009      |  |   |
|   |                         |   | <b>5c. PROGRAM ELEMENT NUMBER</b>                |  |   |
| <b>6. AUTHOR(S)</b><br>Jimin Guo<br><br>E-Mail: <a href="mailto:jimin.guo@mail.mcgill.ca">jimin.guo@mail.mcgill.ca</a>  |                         |   | <b>5d. PROJECT NUMBER</b>                        |  |   |
|   |                         |   | <b>5e. TASK NUMBER</b>                           |  |   |
|   |                         |   | <b>5f. WORK UNIT NUMBER</b>                      |  |   |
| <b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b><br><br>McGill University<br>Montreal QC H3A2T5 CANADA   |                         |   | <b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>  |  |   |
| <b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b><br>U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012  |                         |   | <b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>          |  |   |
|   |                         |   | <b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>    |  |   |
| <b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b><br>Approved for Public Release; Distribution Unlimited   |                         |   |  |  |   |
| <b>13. SUPPLEMENTARY NOTES</b>  |                         |   |  |  |   |
| <b>14. ABSTRACT</b><br><br>The canonical TGFb/Smad signaling axis promotes breast cancer metastasis, as blocking this pathway could slow down metastasis in animal models. Since Smad2 and Smad3 are transcription factors, they are not ideal drug targets. As such, investigating intracellular signaling mechanisms that regulate Smad activity is highly meaningful not only for understanding TGFb's pro-invasive functions in breast cancer but also for identifying new leads to design therapies that block TGFb signaling in metastatic breast cancer.<br><br>We identify two of such mechanisms, mediated through cell signaling molecules GRK2 and BCAR3, which could antagonize TGFb signaling in human breast cancer cells. During the tenure of the traineeship, we performed biochemical studies to elucidate how these signaling molecules could block TGFb/Smad signaling; and performed cell-based functional analysis to determine whether these molecules could modulate TGFb's pro-invasive functions. We found that both GRK2 and BCAR3 were potent inhibitory molecules of Smad activation. They both antagonize TGFb-mediated gene transcription and TGFb-induced breast cancer cell invasion. High expression of GRK2, or BCAR3, associates with lower chance of relapse and distant metastasis among breast cancer patients. As such, mimicking GRK2 or BCAR3's function in breast cancer cells could likely decrease the invasive properties of these cells. |                         |   |  |  |   |
| <b>15. SUBJECT TERMS</b><br>TGFb, Smad, breast cancer, invasion, GRK2, BCAR3  |                         |   |  |  |   |
| <b>16. SECURITY CLASSIFICATION OF:</b>  |                         |   | <b>17. LIMITATION OF ABSTRACT</b>                | <b>18. NUMBER OF PAGES</b>                                   | <b>19a. NAME OF RESPONSIBLE PERSON</b><br>USAMRMC |
| <b>a. REPORT</b><br>U   | <b>b. ABSTRACT</b><br>U | <b>c. THIS PAGE</b><br>U                |  |  | <b>19b. TELEPHONE NUMBER</b> (include area code)  |
|   |                         |   | UU   | 49   |   |

Table of Contents:

|                                    |    |
|------------------------------------|----|
| Introduction .....                 | 1  |
| Body .....                         | 1  |
| Key Research Accomplishments ..... | 3  |
| Reportable Outcomes .....          | 3  |
| Reference .....                    | 3  |
| Appendix A .....                   | 5  |
| Appendix B .....                   | 44 |
| Appendix C .....                   | 46 |

## 1. Introduction:

During breast cancer progression, alongside the development of hormone-independent growth mechanisms, cancer cells have been shown to alter their biological response to the transforming growth factor  $\beta$  (TGF $\beta$ ) [1]. TGF $\beta$  family growth factors, through inducing cell cycle arrest and apoptosis, inhibit proliferation in the mammary epithelium and in differentiated, early stage breast tumors [2-5]. These functions are lost and replaced by tumor promoting and pro-metastatic responses in poorly-differentiated, advanced stage breast tumors [6, 7] In cancer cells representing such tumors, TGF $\beta$  transcriptionally reprograms cells to induce epithelial to mesenchymal transition (EMT), cell migration and invasion[8, 9]. In addition, in the stroma, TGF $\beta$  promotes local and systematic immune suppression, thereby allowing transformed cells to escape immune surveillance, further promoting tumor metastasis [8, 10, 11] Most of the above mentioned biological functions of TGF $\beta$  are attributed to a canonical signaling pathway mediated by the Smad transcription factors [12]. TGF $\beta$  binding to its receptors (type I and type II serine threonine kinases) leads to the recruitment and phosphorylation of Smad2/3 and their association with Smad4. The activated Smads then collectively translocate into the nucleus where they bind to regulatory elements on the promoter regions of their target genes to regulate gene transcription[13]. The canonical TGF $\beta$ /Smad signaling axis is central to TGF $\beta$ -mediated breast cancer cell migration and tumor metastasis. Altering the function of key components of the TGF $\beta$ /Smad signaling, using RNA interference or decoy ligand traps approaches, impairs formation of breast cancer metastasis in experimental models[6, 14, 15]. As such, understanding how intracellular mechanisms regulate Smad signaling provides insights into the biology of metastatic breast cancer and novel means of treatment and prognosis.

During the tenure of the traineeship, I studied two of such mechanisms, namely those mediated through G Protein Coupled Receptor Kinase 2 (GRK2) and Breast Cancer Anti-Estrogen Resistance 3 (BCAR3). During the first two years of the study, we conducted biochemical analysis to investigate how these two signaling molecules could antagonize TGF $\beta$ /Smad signaling. They behave similarly, by antagonizing C-terminal serine phosphorylation on the Smads, thereby blocking Smad activation. However, they do so through different mechanisms. Whereas GRK2 phosphorylates a defined serine/threonine residue on the linker region of the Smad, BCAR3 recruits another signaling molecule, p130Cas, which physically interacts with the C-terminal of the Smads. In the last year of the traineeship, I conducted cell-based biological assays to evaluate whether GRK2 and BCAR3 could modulate TGF $\beta$ 's pro-invasive responses in breast cancer cells. We find that these factors, when overexpressed, remarkably block TGF $\beta$ -mediated cell invasion. While we have technical difficulty to stably transfect these factors into breast cancer cell lines in order to test their effects on invasion *in vivo*, we have changed strategy to adopt a virus infection-based method to generate inducible stably cell lines.

## 2. Body:

### Task 1: Generating stable cell lines expressing ectopic GRK2 and BCAR3.

According to modified SOW, we stably transfected SUM-159 cells and SCP2 cells with GRK2 or BCAR3 expression vectors to select for stable cell lines. We are able to obtain stable expression of FLAG-tagged GRK2 and BCAR3, but at low expression level. We further tested whether these stable cells carry impaired response to TGF $\beta$ . Stable

expression of GRK2 and BCAR3 has modest effects on decreasing TGF $\beta$ -induced transcription from 12CAGA-lux, a Smad-responsive artificial reporter gene (data not shown). This is likely due to the low level of expression of these factors.

To obtain cell lines that allow us to conduct *in vivo* experiments, we have constructed viral vectors for inducible expression of GRK2 and BCAR3 in human breast cancer cells. To do so we have subcloned Flag-tagged human GRK2 or BCAR3 open reading frames into pLVX-TRE3G lentiviral vector, produced viral particles, infected SUM-159 cells and recently established pools of cells resistance to antibiotic selection. We are currently validating inducible expression of GRK2 or BCAR3 by Western blot and Immunofluorescence.

### **Task 2: Evaluate the effects of BCAR3 on Smad signaling and TGF $\beta$ -induced cell invasion.**

In previous funding years, we found that BCAR3 is an endogenous factor in breast cancer cells that antagonizes Smad activation. We further tested whether overexpressing BCAR3 could impair Smad-mediated transcriptional responses. We found that BCAR3 overexpression could effectively block TGF $\beta$ -induced Smad nuclear translocation and Smad-dependent transcription (please see previous reports and manuscript/Appendix A).

TGF $\beta$  induces cell migration and invasion in basal-like metastatic breast cancer cells, such as MDA-MB-231 cells and SCP2 cells. We opted for a real time live cell imaging approach and found that knocking down endogenous BCAR3 in SCP2 cells promoted TGF $\beta$ -induced cell migration (please see attached manuscript). Moreover, knocking down BCAR3 in SCP2 cells resulted in remarkable increases in TGF $\beta$ -induced cell invasion through matrigel (Figure 1/Appendix B). We also obtained similar results using another basal-like breast cancer cell line, BT-549 cells. These results suggest that endogenous BCAR3 is an antagonistic mechanism of TGF $\beta$ 's pro-invasive responses.

In addition to the transwell experiments proposed in the SOW, we also used a gelatin matrix degradation assay to study cell invasion, as this method allows us to visualize single cell invasion and morphology of invadopodia. In MDA-MB-231 cells, TGF $\beta$  remodeled invadopodia structure, from a scattered pattern to a bundled pattern that favors cell invasion. Knocking down BCAR3 facilitated this response, and increased both invadopodia number and total area of digestion in response to TGF $\beta$  (please see manuscript/Appendix A).

### **Task 3. Evaluate the effects of ectopic GRK2 in antagonizing metastasis *in vivo*.**

As discussed in Task 1, we experienced technical difficulty generating stable cell lines that could express ideal levels of GRK2 for *in vivo* studies. To conduct the proposed *in vivo* studies, we are currently selecting viral-infected SUM-159 cells for inducible GRK2 expression. At the main time, we addressed this task using the matrix degradation assay as described in Task 2. We transfected FLAG-tagged GRK2 into MDA-MB-231 cells, allowed cells to invade into gelatin matrix for 48 hours, and then observe the effect of ectopic GRK2 on matrix degradation. Under these conditions, we observed that under each cell there were black dots joining into large areas, representing degradation of fluorescence gelatin matrix. However, this effect seemed to be absent in cells expressing FLAG-tagged GRK2 (Figure 2/Appendix B). Furthermore, we also found that ectopic GRK2 expression in MDA-MB-231 cells could block TGF $\beta$ -induced matrix degradation

(Figure 2/Appendix B). This result serves as a proof-of-principle for our proposed *in vivo* experiments, which we will conduct as soon as we obtain the stable inducible cells.

#### **Task 4. Training.**

With the support of the traineeship, I have attended several courses, training workshops and conferences, as listed in previous annual reports. During the past year, I have attended a symposium hosted by NIH's Integrative Network-Based Cellular Signature program and a symposium hosted by the Cancer Center of Beth Israel Deaconess Medical Center, in Boston MA and on consecutive dates. These events extend my scope of knowledge on Systems Biology and Cancer Biology, respectively. In particular, they further shaped my research interest on breast cancer, to studying mechanisms that influence drug responses and prognosis using genomic and proteomic approaches.

During the tenure of the traineeship, I prepared a first author manuscript reporting the novel role of BCAR3 as an antagonistic factor of Smad signaling. It is currently under peer review. I also contributed to a few manuscripts; two of which are published and one is under peer review (Appendix C).

#### **3. Key Research Accomplishments:**

- Characterize clinical implications of GRK2 and BCAR3 in human breast cancer.
- Characterize Smad mutants as novel inhibitors of Smad signaling.
- Identify BCAR3 to be a novel inhibitor of Smad signaling.
- Evaluate BCAR3's role in antagonizing TGF $\beta$ 's pro-invasive responses.

#### **4. Reportable Outcomes:**

- Manuscripts: one first author manuscript in submission and four co-author manuscripts
- Presentations: three conference poster presentations (Cold Spring Harbor Symposium and AACR conferences) and several oral presentations in local and international conferences
- Training and workshops: Welcome Trust Advanced Course, Confocal Microscopy training course, Beth Israel Deaconess Medical Center Co-clinical workshop, and a series of other workshops and short courses.
- Degree: currently writing my dissertation
- Cell lines: SUM-159 cells overexpressing FLAG-tagged BCAR3 and GRK2; and SCP2 cells overexpressing Smad mutants

#### **5. References:**

1. Massague, J., *TGFbeta in Cancer*. Cell, 2008. **134**(2): p. 215-30.
2. Cao, Y., et al., *TGF-beta repression of Id2 induces apoptosis in gut epithelial cells*. Oncogene, 2009. **28**(8): p. 1089-98.
3. Cipriano, R., et al., *TGF-beta signaling engages an ATM-CHK2-p53-independent RAS-induced senescence and prevents malignant transformation in human mammary epithelial cells*. Proc Natl Acad Sci U S A, 2011. **108**(21): p. 8668-73.
4. Ewen, M.E., et al., *TGF beta inhibition of Cdk4 synthesis is linked to cell cycle arrest*. Cell, 1993. **74**(6): p. 1009-20.

5. Smeland, E.B., et al., *Transforming growth factor type beta (TGF beta) inhibits G1 to S transition, but not activation of human B lymphocytes*. Exp Cell Res, 1987. **171**(1): p. 213-22.
6. Kang, Y., et al., *Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway*. Proc Natl Acad Sci U S A, 2005. **102**(39): p. 13909-14.
7. Muraoka, R.S., et al., *Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases*. J Clin Invest, 2002. **109**(12): p. 1551-9.
8. Lebrun, J.J., *The Dual Role of TGF in Human Cancer: From Tumor Suppression to Cancer Metastasis*. ISRN Molecular Biology, 2012. **2012**: p. 28.
9. Xu, J., S. Lamouille, and R. Derynck, *TGF-beta-induced epithelial to mesenchymal transition*. Cell Res, 2009. **19**(2): p. 156-72.
10. Wilson, E.B., et al., *Human tumour immune evasion via TGF-beta blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity*. PLoS One, 2011. **6**(9): p. e22842.
11. Flavell, R.A., et al., *The polarization of immune cells in the tumour environment by TGFbeta*. Nat Rev Immunol, 2010. **10**(8): p. 554-67.
12. Massague, J. and R.R. Gomis, *The logic of TGFbeta signaling*. FEBS Lett, 2006. **580**(12): p. 2811-20.
13. Shi, Y. and J. Massague, *Mechanisms of TGF-beta signaling from cell membrane to the nucleus*. Cell, 2003. **113**(6): p. 685-700.
14. Padua, D. and J. Massague, *Roles of TGFbeta in metastasis*. Cell Res, 2009. **19**(1): p. 89-102.
15. Dai, M., et al., *A novel function for p21Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFbeta-mediated breast cancer cell migration and invasion*. Breast Cancer Res, 2012. **14**(5): p. R127.

## 6. Appendix:

- A. Manuscript entitled "Breast Cancer Anti-Estrogen Resistance-3 (BCAR3) inhibits TGFbeta/Smad signaling and associates with favorable breast cancer disease outcomes".
- B. Figure 1 and Figure 2
- C. Publications and posters during the tenure of the traineeship

Appendix A:

Breast Cancer Anti-Estrogen Resistance-3 (BCAR3) inhibits TGF $\beta$ /Smad signaling and associates with favorable breast cancer disease outcomes

Jimin Guo<sup>1</sup>, Nadege Fils-Aime<sup>1</sup>, Charles Vincent Rajadurai<sup>2</sup>, Manuel Villatoro<sup>1</sup>, Meiou Dai<sup>1</sup>, Juliana Korah<sup>1</sup>, Morag Park<sup>2</sup>, Suhad Ali<sup>3</sup> and Jean-Jacques Lebrun\*<sup>1</sup>

1. Division of Medical Oncology, Department of Medicine, McGill University Health Center, Montreal, Canada
2. Goodman Cancer Research Centre, Montreal, Quebec, Canada
3. Division of Hematology, Department of Medicine, McGill University Health Center, Montreal, Canada

*\*Correspondence:* Dr. Jean-Jacques Lebrun, Department of Medicine, Royal Victoria Hospital, Suite H7.66, 687 Pine Avenue West, H3A 1A1, Montreal, Quebec, Canada. Tel: (001-514) 934-1934 x34846; Fax: (001-514) 982-0893; E-mail: JJ.Lebrun@mcgill.ca

Jimin Guo: [jimin.guo@mail.mcgill.ca](mailto:jimin.guo@mail.mcgill.ca)  
Nadege Fils-Aime: [nadege.fils-aime@mail.mcgill.ca](mailto:nadege.fils-aime@mail.mcgill.ca)  
Charles Vencent Rajadurai : [charles.rajadurai@mail.mcgill.ca](mailto:charles.rajadurai@mail.mcgill.ca)  
Meiou Dai: [meiou.dai@mail.mcgill.ca](mailto:meiou.dai@mail.mcgill.ca)  
Juliana Korah: [Juliana.korah@mail.mcgill.ca](mailto:Juliana.korah@mail.mcgill.ca)  
Morag Park: [morag.park@mcgill.ca](mailto:morag.park@mcgill.ca)  
Suhad Ali: [suhad.ali@mcgill.ca](mailto:suhad.ali@mcgill.ca)  
Jean-Jacques Lebrun: [jj.lebrun@mcgill.ca](mailto:jj.lebrun@mcgill.ca)

**Abstract:**

In this study, we investigated the role of the Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) gene in breast cancer progression. Our results define a novel function for BCAR3 as a potent inhibitor of the TGF $\beta$  signaling pathway. We found BCAR3 to inhibit Smad activation, Smad-mediated gene transcription, Smad-dependent cell migration and matrix digestion in breast cancer cells. Furthermore, we found BCAR3 gene expression itself to be repressed by TGF $\beta$ , defining a novel positive feedback loop mechanism downstream of the TGF $\beta$ /Smad signaling pathway. Examination of BCAR3 expression levels in large cohorts of breast cancer patients also indicate that BCAR3 bears a true prognostic value in human breast cancer. Indeed, loss of BCAR3 expression in primary breast tumors correlates with distant metastasis free survival (DMFS) and relapse free survival (RFS) poor outcomes, regardless of molecular subtype and treatment. We also found a strong correlation between the loss of BCAR3 expression and lymph node invasion in human breast cancer, further suggesting a role for BCAR3 in preventing disease progression. Traditionally, BCAR3 has been considered to be associated with aggressive breast cancer phenotypes. However, our results indicate that BCAR3 acts as a putative suppressor of breast cancer progression by inhibiting the pro-metastatic TGF $\beta$ /Smad signaling pathway in invasive breast tumors. These data provides new insights into BCAR3's molecular mechanism of action and highlight BCAR3 as a novel TGF $\beta$ /Smad antagonist in breast cancer.

**Keywords:** BCAR3, TGF $\beta$ , Smad, migration, invasion, breast cancer prognosis

**Introduction:**

Breast tumorigenesis and progression are controlled by multiple hormone/growth factor/cytokine signaling pathways, which are ideal therapeutic targets. Targeted therapies against breast cancer, such as those developed towards the Estrogen Receptor alpha (ER $\alpha$ ) or the Her2 receptor tyrosine kinase, have shown some levels of success<sup>1,2</sup>. However, clinical observations also indicate that tumors which initially respond to targeted therapies often relapse and acquire resistance to the treatments<sup>3,4</sup>. Several genes, collectively named Breast Cancer Anti-Estrogen Resistance (BCAR) genes were found to induce estrogen-independent cell growth in estrogen-dependent breast cancer cells<sup>5</sup>. Two members, BCAR1/p130Cas and BCAR3 are found to form a complex by directly interacting with each other<sup>6,7</sup>. Individual overexpression of these genes allows estrogen-dependent breast cancer cells to proliferate under the presence of Tamoxifen<sup>5,8</sup>. Ectopic overexpression of BCAR3 in breast cancer cells activate Src and FAK kinases, leading to p130Cas tyrosine phosphorylation and increased cell attachment to fibronectin and cell motility<sup>7,9</sup>. Therefore, BCAR3 is traditionally considered to play a role in mediating aggressive breast cancer phenotype. However, a previous report suggested BCAR3 expression to correlate with favorable outcome in progression free survival in a cohort of estrogen receptor positive breast cancer patients who had received Tamoxifen<sup>10</sup>. As such, the regulatory role played by BCAR3 in breast cancer cells remained unclear and controversial and is aimed to be addressed in this study.

During breast cancer progression, alongside the development of hormone-independent growth mechanisms, cancer cells have been shown to alter their biological response to the transforming growth factor  $\beta$  (TGF $\beta$ )<sup>11</sup>. TGF $\beta$  family growth factors, through inducing

cell cycle arrest and apoptosis, inhibit proliferation in the mammary epithelium and in well-differentiated, early stage breast tumors<sup>12-15</sup>. These functions are lost and replaced by tumor promoting and pro-metastatic responses in poorly-differentiated, advanced stage breast tumors<sup>16,17,18,19</sup>. In cancer cells representing such tumors, TGF $\beta$  transcriptionally reprograms cells to induce epithelial to mesenchymal transition (EMT), cell migration and invasion<sup>19,20,19</sup>. In addition, in the stroma, TGF $\beta$  promotes local and systematic immune suppression, thereby allowing transformed cells to escape immune surveillance, further promoting tumor metastasis<sup>19,21,22</sup>. Most of the above mentioned biological functions of TGF $\beta$  are attributed to a canonical signaling pathway mediated by the Smad transcription factors<sup>23</sup>. TGF $\beta$  binding to its receptors (type I and type II serine threonine kinases) leads to the recruitment and phosphorylation of Smad2/3 and their association with Smad4. The activated Smads then collectively translocate into the nucleus where they bind to regulatory elements on the promoter regions of their target genes to regulate gene transcription<sup>24</sup>. The canonical TGF $\beta$ /Smad signaling axis is central to TGF $\beta$ -mediated breast cancer cell migration and tumor metastasis. Altering the function of key components of the TGF $\beta$ /Smad signaling, using RNA interference or decoy ligand traps approaches, impairs formation of breast cancer metastasis in experimental models<sup>16,25,26</sup>. As such, understanding how intracellular mechanisms regulate Smad signaling provides insights into the biology of metastatic breast cancer and novel means of treatment and prognosis.

In this study, we define a novel regulatory pathway directly linking the TGF $\beta$ /Smad signaling axis to BCAR3. Our data highlight BCAR3 as a potent inhibitor of the TGF $\beta$ /Smad signaling pathway. We found BCAR3 to promote an interaction between

Smad2/3 and p130Cas, leading to inhibition of Smad activation, Smad-mediated gene transcription and Smad-dependent cell migration in breast cancer cells. Interestingly, we also found BCAR3 expression to be controlled by TGF $\beta$  itself, as TGF $\beta$  treatment decreases BCAR3 expression in a Smad-dependent manner. This defines a novel positive regulatory feedback loop, through which TGF $\beta$  signaling further induces its effects by blocking expression of the Smad inhibitor, BCAR3. We also report a true prognostic value of BCAR3 in human breast cancer. We found that loss of BCAR3 expression in primary breast tumors correlates with poor outcomes, regardless of molecular subtype and treatment. Taken together, our study indicates that BCAR3 is a novel antagonist of TGF $\beta$  functions in breast cancer cells, and loss of BCAR3 function correlates with poor outcomes in breast cancer patients.

#### **Methods:**

Gene expression analysis: Using GEO, patient outcomes were queried for 10 years. Compiled cohorts of patients were divided as described in the text, based on reading from an Affymetrix BCAR3 probe on microarrays (204032\_at). In the analysis of endocrine treated patients, log rank readings from the probe targeting BCAR3 were extracted from the NCBI-GEO dataset GDS807, and plotted.

Cell culture: MCF-7, MDA-MB-231 and BT-549 cells were obtained from ATCC and maintained in DMEM (Hyclone) supplemented with 10% FBS. Inducible BCAR3 MCF-7 cells were maintained in DMEM supplemented with 10% FBS, 100 $\mu$ g/ml G418 and 1 $\mu$ g/ml Puromycin. SUM-149PT and SUM-159PT cells were obtained from Dr. Stephen Ethier, and were maintained in F-12 nutrient mixture (Hyclone) supplemented with 5%

FBS, 5µg/ml insulin and 1µg/ml hydrocortisone. SCP2 cells were obtained from Dr. Joan Massague.

Constructs and Transfection: BCAR3 siRNAs (catalogue number SASI\_Hs01\_00236261 and SASI\_Hs02\_00335873), p130Cas siRNA (SASI\_Hs02\_00345830) and scrambled control siRNA were manufactured by Simga-Aldrich. In the Smad phosphorylation experiments, the scrambled control siRNA was manufactured by Ambion (Ambion scrambled control #2). Dr. Laurence Quilliam kindly provided the FLAG-tagged mouse AND-34 expression vector. The GST-tagged rat p130Cas expression vector was obtained from Addgen (catalogue number 15001). Transfections were carried out using Lipofectamine 2000 reagent (Life Technologies) according to the manufacturer's instructions.

SDS-PAGE and Western blot: Cells were lysed with RIPA buffer containing 1% Triton-X, protease inhibitors and phosphatase inhibitors. Total protein lysates were quantified and 50 µg lysates were separated by SDS-PAGE followed by transferring onto nitrocellulous membrane and subjected for Western blot as previously described. To obtain nuclear extracts, cells were lysed with PBS containing 1% NP-40. The nucleus were washed in the lysis buffer for multiple times and lysed with loading dye containing SDS, as described in a protocol described by the others.

RNA extraction, reverse transcription and real-time PCR: Total RNAs were extracted with Trizol reagent (Life Technologies) following the manufacturer's instructions. RNA samples were reverse-transcribed using MML-V (Life Technologies) and subjected for real-time PCR, with ribosomal 18S RNA as internal control. PCR reactions were carried

out using Ssofast Evergreen super mix (Bio-rad) following the manufacturer's instructions

Cell viability assay: Inducible MCF-7 cells were plated into 96-well plates (5,000 cells/well), and cultured in complete DMEM with or without doxycycline for 96 hours. Cells were then serum starved with or without doxycycline. Under each condition, paired wells of cells were treated with or without 200pM TGF $\beta$  for 72 hours. Cells were then incubated with MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) for 4 hours, gently washed with PBS. Each well received 200 $\mu$ l DMSO to suspend converted formazan, subjected for absorption reading at 570nm.

Confocal microscopy: Cells transfected with FLAG-AND-34 were seeded on cover slips, treated as described in figure legends, fixed with 3.7% paraformaldehyde in PBS for 15 minutes, and then permeabilized with 0.1% triton-X in PBS for 3 minutes. After blocking for 1 hour at room temperature in 2% BSA in PBS, cells were co-stained with a mouse anti-FLAG antibody (#M2, Sigma, 1:500) and a rabbit anti-phospho-Smad3 antibody (#9520, Cell Signaling, 1:500), or Alexa568-labeled Phalloidin (Life Technologies). Cells were then stained with Alexa488-labeled goat-anti-mouse secondary antibody (Life Technologies, 1:500) and Alexa568-labeled goat-anti-rabbit secondary antibody (Life Technologies, 1:500), except in the case when Phalloidin used. Following DAPI counterstaining and mounting, images were taken using a X63 immersion oil objective on an LSM780 confocal microscope (Carl Zeiss). Images were taken in a multi-track scanning mode at a 1024X1024 resolution. Excitation wavelengths were set at 490nm (Argon laser) and 570nm (HeNe laser) for detecting emission wavelengths at around 520nm (for Alexa-488) and around 600nm (for Alexa-568), respectively. Images were

converted to 16-bit TIFF RGB format by ImageJ. Images of individual channels were converted to grey scale, and merged images were set at auto-contrast using Photoshop CS6. Quantifications of phospho-Smad levels were performed using ImageJ software (5 images per condition).

Migration Assay: Scratch-based migration assays were carried out with an Incucyte automatic system (Essen Bioscience) according to the manufacturer's protocol. Briefly, cells transfected with siRNA were seeded onto I96-well ImageLock plate one day post-transfection at a density of 50,000 cells per well. Cells were then starved overnight. Monolayers of cells were scratched using a scratching apparatus that produced highly identical scratches in each well. Cells were then treated with 100pM TGF $\beta$ . The Incucyte system was programmed to obtain real-time phase contrast image of the wounded at 12 time points. In the BCAR3 siRNA experiments, images were taken every 4 hours for 48 hours. In the double knocking-down experiments, images were taken every 3 hours for 36 hours. At least 3 independent experiments were performed, and each experiment contains 4 biological replicates for every condition. Results from one representative experiment were shown. Cell migration was quantified and expressed as Relative Wound Density, which indicates the ratio of sharpness of the wounded area and of adjacent non-wounded area.

Gelatin digestion assay: Cover slips were first treated with poly-D-lysine and glutaraldehyde, then coated with 0.1% pig gelatin solution containing Alexa488-conjugated gelatin for 3 hours. The slides were quenched with 0.1% sodium borohydride solution prior to be seeded with 100,000 cells. Six hours after seeding, the cells were starved and treated with or without 200pM TGF $\beta$  for 36 hours. Fixing, staining and

imaging procedures are described above in the Confocal Microscopy section. Images show representative images of 3 independent experiments. Quantifications show averages and standard deviations of 10 cells on 7-10 LSM image files of a representative experiment.

### **Results:**

#### 1. BCAR3 expression correlates with favorable breast cancer disease outcome.

BCAR3 is considered to be associated with aggressive disease phenotypes as it promotes estrogen-independent cell proliferation, cell migration, and cell-ECM contacts<sup>5,7,9,27,28</sup>. However, a clinical study suggests BCAR3 expression to be a single factor to predict favorable progression-free survival of patients who received Tamoxifen treatment<sup>10</sup>. To investigate BCAR3's clinical implications, we used Gene Expression-Based Outcome for Breast Cancer Online (GOBO)<sup>29</sup> to generate Kaplan-Meier survival curves of breast cancer patients from published microarray datasets in the NCBI Genome Omnibus. Consistent with the above mentioned study<sup>10</sup>, we found some level of correlation (p=0.09, data not shown) between high BCAR3 expression and low rate of disease progression in Tamoxifen-treated patient. More importantly, we extended our study to examine progression-free survival (PFS) to two distinct cohorts of patients: a compiled cohort that underwent various treatment plans and a true-prognostic cohort that received no systematic therapy. As shown in Fig.1A, in the compiled cohort, we found that those with low BCAR3 expression (grey) had significantly worse prognosis compared to patients with high BCAR3 levels (red), indicating that BCAR3 expression favors progression-free survival for patients who received various treatment plans. We also found a similar trend in non-treated patient cohort (Fig. 1B). This not only demonstrates a true prognostic

value for BCAR3, but also implicates that loss of BCAR3 expression may be involved in breast cancer progression. We further analyzed and correlated BCAR3 expression levels with distant metastasis or disease relapses. Consistently, we found BCAR3 expression to positively correlate with higher distant metastasis free survival (DMFS) in both an overall cohort and a non-treated cohort of patients (Fig. 1C and 1D, respectively). Furthermore, BCAR3 expression also correlated with higher relapse free survival (RFS) in the overall cohort (Fig. 1E). In the non-treated cohort, when patients are separated by median expression level, no significant link is observed between BCAR3 and RFS (data not shown). However, when patients are separated into more refined groups, we found that the group that expressed the lowest level of BCAR3 had significant worse prognosis, whereas risks of the 4 other groups were comparable (Fig. 1F). This suggests a dose-dependent like effect of BCAR3, whereas a slight decrease of BCAR3 expression may not be detrimental to relapse-free survival, a severe loss of BCAR3 expression correlates with markedly increased tumor relapse.

Complimentary to these findings, we further investigated whether established disease characteristics can be traced backwards to BCAR3 expression levels in primary breast tumors. We analyzed both disease relapse and lymph node positivity, as they represent two critical indicators of the aggressiveness of the disease. To do so, we grouped patients based on established outcomes and surveyed for difference in BCAR3 expression between groups. In a cohort of patients with ER+ breast tumors treated with endocrine therapy for 5 years (NCBI-GEO GDS807)<sup>30</sup>, those who developed disease relapse had lower levels of BCAR3 expression in their primary tumors (Figure 1G) and lower BCAR3 transcript abundance (data not shown). These results, together with Kaplan-

Meier analysis, highlight a high degree of overlapping between patients with low BCAR3 levels and patients with disease relapse. Additionally, using the ROCK breast cancer functional genomics database<sup>31</sup>, from a CGH dataset designed to identify copy number abnormalities in breast cancer<sup>32</sup>, we clearly established a correlation between advanced Tumor N-stage/lymph node status and loss of heterozygosity at BCAR3 alleles in breast cancer patients,. Particularly, combined loss and deletion of BCAR3 alleles increased from 18% in N0 tumors (no lymph node invasion), to 31% in N1 tumors (tumor cells in regional lymph nodes), and to 50% in N2 tumors (tumor cells in regional and distant lymph nodes). Altogether, these results indicate that loss of BCAR3 expression correlates with an invasive tumor phenotype, increased lymph node involvement. Concomitantly, high BCAR3 expression levels are predictive of significantly improved progression-free, distant metastasis free and relapse free survivals. Our data also suggest that BCAR3 likely plays a tumor suppressor-like role by preventing disease progression in breast cancer patients, independently of treatments received.

## 2. BCAR3 antagonizes TGF $\beta$ -induced Smad phosphorylation and nuclear translocation.

We then sought to investigate the molecular mechanisms by which BCAR3 exerts this protective role in breast cancer cells. Interestingly, a BCAR3-interacting protein, p130Cas, was previously shown to directly interact with Smad2/3, thereby blocking Smad C-terminal serine phosphorylation and activation, resulting in an inhibition of TGF $\beta$  signaling<sup>33,34</sup>. As the TGF $\beta$ /Smad signaling pathway has been shown to play a prominent role in breast cancer progression and tumor metastasis, we investigated whether BCAR3 could regulate TGF $\beta$ /Smad signal transduction. We initially examined the relative protein expression levels of BCAR3 and p130Cas in a panel of breast cancer

cell lines representing different molecular subtypes and phenotypes of breast tumors. Similar to previously reported findings<sup>35</sup>, we found that BCAR3 expression level was relatively high in estrogen-independent breast cancer cells (Fig.2A). Additionally, BCAR3 expression generally correlated with breast cancer subtype. Luminal-like MCF-7 and SK-BR-3 cells express relatively low levels of BCAR3, whereas basal-like MDA-MB-231, SCP2, BT-549 and SUM-149PT cells expressed relatively high levels of BCAR3 (Fig.2A). However, SUM-159PT cells, which are ER- and estrogen-independent in culture and as xenograft, also expressed a relatively low level of BCAR3 (Fig. 2A). This may likely be due to the anaplastic nature of the origin of these cells<sup>36</sup>. Furthermore, p130Cas is fairly abundant in all cells tested, and its expression did not seem to correlate with either ER status or cancer subtype (Fig.2A). These results suggest that while p130Cas expression maybe a universal event in most types of breast cancer cells and tumors, high BCAR3 expression is likely specific in cells of a basal like breast cancer phenotype.

We used both loss-of-function and gain-of-function approaches to investigate whether BCAR3 is involved in regulating the TGF $\beta$ /Smad signaling axis in breast cancer cells. SCP2 cells were derived as a sub-progeny of MDA-MB-231 cells, and are highly invasive and highly responsive to TGF $\beta$ <sup>26,37</sup>. Moreover, these cells express high levels of BCAR3 among the panel of breast cancer cell lines that we tested (Fig.2A). In SCP2 cells, TGF $\beta$  induced Smad3 phosphorylation in time dependent manner, however, this effect was markedly potentiated when BCAR3 gene expression was silenced, using a specific siRNA, suggesting that BCAR3 is inhibitory to TGF $\beta$  and Smad signaling (Fig.2B).

To further address this inhibitory role, we examined the effect of ectopic BCAR3 on Smad signaling in MCF7 cells, which express fairly low or undetectable endogenous BCAR3 levels. We used an inducible stable MCF-7 cell line that overexpresses BCAR3 under the control of a tet-off promoter under normal culture conditions<sup>7</sup>. As shown in Fig.2C, removal of doxycycline greatly induced BCAR3 expression in these cells (middle panel). Interestingly, TGF $\beta$ -induced Smad phosphorylation, observed in the absence of BCAR3, was almost completely blocked when BCAR3 was overexpressed (upper panel). Furthermore, induced BCAR3 expression in MCF-7 cells also impaired Smad nuclear translocation in response to TGF $\beta$  (Fig.2D). Together, these results clearly demonstrate that BCAR3 expression is inhibitory to TGF $\beta$ -induced Smad phosphorylation and Smad nuclear translocation.

We also investigated the effect of BCAR3 overexpression on TGF $\beta$  signaling using fluorescent confocal microscopy. We transiently over expressed FLAG-tagged AND-34 (the mouse homologue of BCAR3) in SUM-159-PT cells, which express low endogenous BCAR3 levels. This allowed us to observe both cells overexpressing BCAR3 and non-overexpressing cells in the same field (Fig.2E). Interestingly, cells expressing FLAG-AND-34/BCAR3 displayed weaker overall phospho-Smad3 signals, compared to non-transfected cells in the same field, under both resting and TGF $\beta$  stimulated conditions (Fig.2E). We further quantified Smad3 phosphorylation levels in 5 original confocal images for each experimental condition. As shown in Fig.2F, TGF $\beta$ -induced Smad3 phosphorylation was remarkably impaired in cells overexpressing BCAR3, further confirming the results obtained by immunoblot analysis (Fig.2A-D).

3. BCAR3 inhibits TGF $\beta$ -mediated Smad transcriptional activity and target gene expression.

We then investigated whether modulating BCAR3 levels could alter Smad-mediated transcriptional activity using a Smad-responsive reporter construct, 12CAGA-lux, which contains 12 repeats of minimal Smad binding site upstream of the firefly luciferase open reading frame. As shown in Fig.3A, TGF $\beta$  strongly induced luciferase activity in SCP2 cells transfected with the 12CAGA-lux construct. However, knocking down endogenous BCAR3 using a pool of 2 specific siRNAs against BCAR3 resulted in significant increases in both basal and TGF $\beta$ -induced luciferase activity (Fig.3A). Consistently, transient transfection of AND-34 (mouse homologue of BCAR3) into SUM-159-PT cells resulted in significant decreases in both basal and TGF $\beta$ -induced luciferase activity (Fig.3B). We further tested, by real-time PCR, whether BCAR3 could alter the expression of *bona fide* TGF $\beta$  target genes. Connective tissue growth factor (CTGF)<sup>38</sup>, PAI-1<sup>39,40</sup> and Smad7<sup>41</sup> were previously reported to be up-regulated by TGF $\beta$  in a Smad-dependent manner. Induced BCAR3 expression in MCF-7 cells almost completely blocked TGF $\beta$ 's effects to induce CTGF and Smad7, and also remarkably impaired TGF $\beta$ 's effect to induce PAI-1 expression (Fig. 3C). The difference in effectiveness may be due to involvement of Smad-independent mechanisms downstream of TGF $\beta$ . Taken together, these results indicate BCAR3 antagonizes Smad transcriptional activity.

MCF-7 cells are luminal-like, estrogen responsive, and relatively well-differentiated. These cells retain partial cytostatic response to TGF $\beta$ . We therefore investigated whether ectopic BCAR3 could antagonize TGF $\beta$ 's growth inhibitory effects in these cells. Stable MCF-7 cells cultured with doxycycline expressed low level of BCAR3. TGF $\beta$  treatment

resulted in 25% reduction in cell viability, as determined by an MTT cell viability assay. Stable BCAR3 expression, on the other hand, reversed TGF $\beta$ 's effect, resulting in less than 10% reduction in cell viability (Fig.3D). As such, ectopic BCAR3, through inhibition of Smad-mediated transcriptional activity, also inhibits Smad-dependent cytostatic effects.

#### 4. BCAR3 antagonizes TGF $\beta$ 's pro-migratory and pro-invasive responses.

A hallmark effect of TGF $\beta$  in breast cancer cells, particularly in basal-like and triple-negative cells, is single cell migration<sup>17,26,42,43</sup>. Lines of evidence suggest that TGF $\beta$  reprograms transcriptional profiles in breast cancer cells to induce epithelial to mesenchymal transition, formation of filopodia, and switching from collective cell migration to single cell migration and ultimately to facilitate intravasation<sup>26,42,44,45</sup>. These effects, although not necessarily concomitant, highlight the pro-migratory role of TGF $\beta$ . As such, we investigated whether modulating BCAR3 levels in basal-like breast cancer cells could affect TGF $\beta$ -induced cell migration. For this, we silenced endogenous BCAR3 gene in SCP2 cells using 2 specific siRNAs, and examined TGF $\beta$ -induced cell migration using the Incucyte time-lapse video imaging migration assay, as previously described<sup>26</sup>. This method couples wound-healing assay with quantitative imaging, and present cell migration by relative wound density, which is the real-time ratio between cell densities within the initial wound area to cell density of adjacent, non-wounded area. As such, this method precludes a net change in cell number over time due to cell proliferation.

TGF $\beta$  induced time-dependent migration of SCP2 cells (Fig.4A and Fig.4B). The effect was detectable as early as 12 hrs following stimulation of the cells and further increased

over time to reach a plateau at 48 hours. Cell density in the wounded area is slightly over 52% of that of the adjacent area. TGF $\beta$  treatment resulted in an about 10% increase in relative cell density, indicative of more cells in the wounded area. Individual siRNAs against BCAR3 decreased cell migration; marked by only about 42% increase in relative wound density after 48 hours (Fig.4A). This is consistent with previous findings that ectopic BCAR3 expression increases cell migration<sup>9</sup>. Interestingly, cells transfected with the siRNAs displayed an increased response to TGF $\beta$ , marked by about 15% increase in relative cell density (Fig. 4A). The 2 siRNA constructs seemed to have similar effects. As such, these data indicate that endogenous BCAR3 is an antagonistic molecule of TGF $\beta$ -induced cell migration.

Single cell migration requires actin being organized into treadmilling filaments oriented toward lamellipodia<sup>46</sup>. As such, we investigated whether ectopic BCAR3 expression could antagonize TGF $\beta$ 's effects on the formation of these structures in SUM-159-PT cells, since these cells express a low level of endogenous BCAR3. Cells were transiently transfected with the FLAG-AND34 (BCAR3) cDNA to allow for the examination of both positive and negative BCAR3 overexpressing cells in the same field. In the absence of BCAR3 overexpression, TGF $\beta$  induced a network of elongated actin stress fibers aligned toward filopodia-like structures, indicative a pro-migratory phenotype (Fig.4C, white arrows). In contrast, cells overexpressing BCAR3, although still contained actin filaments, failed to display dominant filopodia-like structures. Rather, they contained relatively short, branched fibers that oriented towards all directions, even when they were stimulated with TGF $\beta$  (Fig.4C, yellow arrows). We observed these phenotypes with virtually all transfected cells. Taken together, these data demonstrate that BCAR3 could

antagonize TGF $\beta$ 's pro-migratory function, likely by interfering with TGF $\beta$ -mediated actin filament rearrangement and filopodia formation.

Digestion of extracellular matrix is both a major event during cell invasion and an indication of aggressive property of cancer cells. TGF $\beta$  acts as a potent pro-invasive factor in breast cancer and it was previously that this growth factor could increase digestion of a gelatin matrix by MDA-MB-231 cells, using a matrix degradation assay<sup>47</sup>. As such, we investigated whether endogenous BCAR3 could antagonize the TGF $\beta$ 's pro-invasive effects. As shown in Fig. 5, mock-transfected and control siRNA transfected MDA-MB-231 displayed low of invasive properties under basal conditions. Indeed, when plated on coverslips coated with Alexa488-tagged gelatin, these cells produced small and scattered areas of digestion underneath their bodies, observed as dark spots under confocal microscope (as indicated by the yellow arrows in Fig. 5A). Under these conditions, mock transfected and control siRNA transfected MDA-MB-231 cells treated with TGF $\beta$  displayed a clear increase in the total area of digested matrix (Fig. 5A and 5B). Many of these digested areas were elongated, indicative of cell movement during matrix digestion (Fig. 5A). Noticeably, instead of scattering underneath the cell body, elongated digestion spots tend to aggregate at the cell protrusions, overlapping with the lamellipodia-like structures formed by bundled actin filaments (white arrows). These data suggest that in addition to increasing digestion of gelatin matrix, TGF $\beta$  also affects the localization of the invadopodia in MDA-MB-231 cells, and remodels their structure from a scattered to an aggregated pattern. Interestingly, transfection of MDA-MB231 cells with a pool of BCAR3 siRNAs significantly potentiated TGF $\beta$ 's effects on matrix digestion, as illustrated by the large areas of digested gelatin (Fig.5A). Particularly, these areas were

formed by multiple elongated spots roughly parallel to each other's. These spots also appeared to be longer than those formed in control cells. Efficiency of the siRNA knockdown was verified by Western blotting, as shown in Fig.5C. Taken together, these results indicate that BCAR3 gene silencing, by means of RNA interference, potentiates TGF $\beta$ -induced invadopodia activity and matrix digestion, strongly suggesting that endogenous BCAR3 inhibits TGF $\beta$ -induced invadopodia remodeling and matrix digestion.

#### 5. BCAR3 requires p130Cas to antagonize Smad signaling.

Previous studies indicated that the p130Cas physically interacts with Smad2/3 and antagonize Smad activation<sup>33,34</sup>. As p130Cas also interacts with BCAR3, this prompted us to investigate whether p130Cas is involved in BCAR3-mediated inhibition of TGF $\beta$ /Smad signaling. Using co-immunoprecipitation analysis in SCP2 cells, we found p130Cas to be constitutively associated with Smad2/3 (Fig.6A). However, knocking down endogenous BCAR3 expression, by means of RNA interference, effectively impaired this association, suggesting that endogenous BCAR3 promotes the interaction between p130Cas and Smad2/3 (Fig.6A).

We next investigated if BCAR3 also required p130Cas to modulate TGF $\beta$ -induced cell migration. Transfecting cells with siRNAs targeting BCAR3 and p130Cas both decreased basal cell migration, and increased TGF $\beta$ -induced cell migration (not shown and Fig. 6B, respectively). However, upon silencing p130Cas, BCAR3 siRNA lost the effect to further potentiate TGF $\beta$ -induced cell migration (Fig. 6C). Indeed, TGF $\beta$  stimulation resulted in about 40% increase in cell migration in mock-transfected cells at 36 hours post-stimulation. Transfecting cells with BCAR3 siRNA, or p130Cas siRNA, or both, all

resulted in about 70% increases. Co-transfection of the 2 siRNAs did not have a more-than-additive effect (Fig. 6D), suggesting that BCAR3 requires the presence of p130Cas to antagonize TGF $\beta$  function. Altogether, these data suggest that BCAR3 modulates an interaction between p130Cas and Smad2/3, thereby blocking TGF $\beta$  /Smad-mediated cell migration.

#### 6. BCAR3 mediates a positive feedback of TGF $\beta$ signaling in breast cancer cells.

Despite of extensive studies on the molecular functions of BCAR3, there is no report on how BCAR3 gene expression is regulated. As cellular signaling pathways are often modulated by feedback regulatory loop mechanisms to ensure defined signaling intensity and duration, we investigated whether TGF $\beta$  signaling itself could modulate BCAR3 gene expression. For this, we stimulated a panel of breast cancer cell lines with TGF $\beta$  for 24 hours, and examine the protein level of BCAR3. As shown in Fig.7A, TGF $\beta$  treatment resulted in a remarkable decrease in BCAR3 protein levels in all cell line tested, highlighting BCAR3 as a novel target for TGF $\beta$  signaling. Furthermore, our results also indicate that TGF $\beta$ -mediated suppression of BCAR3 gene expression depends on the canonical Smad2/3 signaling, as silencing either Smad2 or Smad3 gene expression in BT-549 cells using specific siRNAs in BT-549 cells almost completely abolished TGF $\beta$ 's effect in decreasing BCAR3 protein expression (Fig. 7B). Taken together, our results define a positive feedback loop mechanism, by which TGF $\beta$ /Smad signaling transcriptionally repress expression of its own inhibitory molecule, BCAR3, further leading to enhanced TGF $\beta$ /Smad signaling in breast cancer cells (Fig. 7C).

#### **Discussion:**

In this study, we defined a novel role for BCAR3 to antagonize the canonical TGF $\beta$  signaling by promoting an interaction between p130Cas and the Smad transcription factors. The inhibitory effect of BCAR3 on TGF $\beta$ /Smad signaling is observed in all breast cancer cell lines tested, regardless of their molecular phenotype and biological responses to TGF $\beta$ . While TGF $\beta$  efficiently induces growth arrest in normal mammary epithelial cells and early breast carcinoma, these cytostatic responses are lost in more advanced, invasive breast tumors and replaced by TGF $\beta$ -induced tumor promoting and pro-metastatic responses<sup>48,49</sup>. In invasive, basal-like breast cancer cells, such as MDA-MB-231, SCP2 and SUM-159-PT, BCAR3 potently antagonizes TGF $\beta$ 's effects on cell migration, formation of filopodia-like structures and digestion of gelatin matrix. On the other hand, in the luminal-like, ER+ MCF7 cells, BCAR3 overexpression antagonized TGF $\beta$ 's cytostatic effect. These findings imply that the novel function of BCAR3 to inhibit Smad signaling is likely a conserved mechanism among the different molecular subtypes of breast cancer.

Interestingly, we found BCAR3 to be a novel target gene of TGF $\beta$  in breast cancer cells. TGF $\beta$  decreased BCAR3 protein expression in multiple breast cancer cells. This effect appeared to be Smad-dependent, as it could be abolished by knocking down either Smad2 or Smad3. These data are the first to describe a molecular mechanism by which BCAR3 expression is being regulated. More importantly, our data define a positive feedback mechanism downstream of TGF $\beta$ /Smad signaling. It is known that a few negative feedback loops exist to fine-tune TGF $\beta$  signaling, such as those mediated by Smad7<sup>41</sup> and GRK2<sup>50</sup>. Both of these targets were shown to be being up-regulated by TGF $\beta$ , further leading to termination of Smad signaling<sup>41,50,51</sup>. To our knowledge, BCAR3 serves as the

first example of a positive feedback loop of TGF $\beta$ /Smad signaling, whereby TGF $\beta$  signaling itself can decrease the expression levels of its inhibitor BCAR3, further leading to enhanced and potentiated TGF $\beta$ /Smad signaling. Such a mechanism may be important for maintaining a steady response to TGF $\beta$ .

It has been established that active Smad signaling contributes to breast cancer local invasion and distant metastasis. Having defined BCAR3 as a novel TGF $\beta$ /Smad inhibitory molecule, this may account for the low BCAR3 expression levels observed in primary breast tumors associated with worse prognosis and higher chances of disease progression. Indeed, low BCAR3 levels may release tumor cells from its inhibitory effect on Smad signaling, leading to enhanced, more potent TGF $\beta$  activity and tumor progression. Results from our clinical data survey and analysis define BCAR3 as a single factor whose expression level is predictive of clinical outcomes in breast cancer patients. Moreover, we also found that patients with lymph node metastasis tend to carry loss of heterozygosity at BCAR3 alleles, indicating that BCAR3 has some features of a tumor suppressor-like gene to prevent disease progression.

**Conclusion:**

Taken together, our study identified a novel positive feedback loop mechanism downstream of the canonical TGF $\beta$ /Smad signaling axis, mediated by a breast cancer anti-estrogen resistance gene, BCAR3. We report a novel role of BCAR3 to antagonize Smad signaling, efficiently leading to inhibition of the TGF $\beta$ 's biological functions in breast cancer cells. Our results also highlighted a true prognostic value for BCAR3 in human breast cancer, as we found low BCAR3 expression levels in primary breast tumors correlates with poor outcomes regardless of treatment plans. Our study provides new insights into BCAR3's mechanism of action, and suggests a need to re-evaluate BCAR3's implications in breast cancer pathology.

**Abbreviations:**

BCAR3: Breast Cancer Anti-Estrogen Resistance 3; DMEM: Dulbecco's modified Eagle's medium; DMFS: distant metastasis free survival; ER: estrogen receptor; FBS: fetal bovine serum; MTT: thiazolyl blue tetrazolium bromide; OS: overall survival; RFS: relapse free survival; TGF $\beta$ : transforming growth factor-beta.

**Competing interests:**

The authors declare no competing interests.

**Author contribution:**

JG and JJJ designed the experiments, involved in all experiment procedures, analysis and interpretation, and wrote the manuscript. JK, MD and NFA performed some of the experiments. CVR and MP assisted in designing matrix degradation assays. SA assisted in designing experiments and interpreting results.

**Acknowledgements:**

We would like to thank Drs A. Bouton and M. Guerrero for providing the inducible BCAR3 overexpressing MCF7 cell line, Drs S. Ethier, J. Massagué, W. Muller, L. Quilliam and P. Siegel for sharing cell lines and expression vectors, and Dr. M. Wendt for discussions. We would also like to thank Dr. M. Fu at the Imaging Core Facility of McGill University Health Center for technical advice. This work is supported by an operating grant from the Canadian Institutes of Health Research (CIHR) to J.J.L. J.G. is supported by a traineeship from US Congressionally Directed Medical Research Program (CDMRP). J.K. and C.V.R. receive Frederick Banting and Charles Best Canada Graduate Scholarships from the CIHR. M.D. receives a doctoral scholarship from the Fonds de la recherche en santé du Québec (FRSQ). J.J.L. is the recipient of the McGill Sir William Dawson Research Chair.

## References:

- 1 Riggs, B. L. & Hartmann, L. C. Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. *The New England journal of medicine* **348**, 618-629, doi:10.1056/NEJMra022219 (2003).
- 2 Shak, S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. *Seminars in oncology* **26**, 71-77 (1999).
- 3 Cornez, N. & Piccart, M. J. [Breast cancer and herceptin]. *Bulletin du cancer* **87**, 847-858 (2000).
- 4 Jordan, V. C. How is tamoxifen's action subverted? *Journal of the National Cancer Institute* **92**, 92-94 (2000).
- 5 van Agthoven, T. *et al.* Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. *The EMBO journal* **17**, 2799-2808, doi:10.1093/emboj/17.10.2799 (1998).
- 6 Gotoh, T., Cai, D., Tian, X., Feig, L. A. & Lerner, A. p130Cas regulates the activity of AND-34, a novel Ral, Rap1, and R-Ras guanine nucleotide exchange factor. *The Journal of biological chemistry* **275**, 30118-30123, doi:10.1074/jbc.M003074200 (2000).
- 7 Schuh, N. R., Guerrero, M. S., Schrecengost, R. S. & Bouton, A. H. BCAR3 regulates Src/p130 Cas association, Src kinase activity, and breast cancer adhesion signaling. *The Journal of biological chemistry* **285**, 2309-2317, doi:10.1074/jbc.M109.046631 (2010).
- 8 Dorssers, L. C. *et al.* Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway. *Breast cancer research : BCR* **7**, R82-92, doi:10.1186/bcr954 (2005).
- 9 Riggins, R. B., Quilliam, L. A. & Bouton, A. H. Synergistic promotion of c-Src activation and cell migration by Cas and AND-34/BCAR3. *The Journal of biological chemistry* **278**, 28264-28273, doi:10.1074/jbc.M303535200 (2003).
- 10 van Agthoven, T. *et al.* Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* **27**, 542-549, doi:10.1200/JCO.2008.17.1462 (2009).
- 11 Massague, J. TGFbeta in Cancer. *Cell* **134**, 215-230, doi:10.1016/j.cell.2008.07.001 (2008).
- 12 Cao, Y. *et al.* TGF-beta repression of Id2 induces apoptosis in gut epithelial cells. *Oncogene* **28**, 1089-1098, doi:10.1038/onc.2008.456 (2009).
- 13 Cipriano, R. *et al.* TGF-beta signaling engages an ATM-CHK2-p53-independent RAS-induced senescence and prevents malignant transformation in human mammary epithelial cells. *Proceedings of the National Academy of Sciences of the United States of America* **108**, 8668-8673, doi:10.1073/pnas.1015022108 (2011).
- 14 Ewen, M. E., Sluss, H. K., Whitehouse, L. L. & Livingston, D. M. TGF beta inhibition of Cdk4 synthesis is linked to cell cycle arrest. *Cell* **74**, 1009-1020 (1993).

- 15 Smeland, E. B. *et al.* Transforming growth factor type beta (TGF beta) inhibits G1 to S transition, but not activation of human B lymphocytes. *Experimental cell research* **171**, 213-222 (1987).
- 16 Kang, Y. *et al.* Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. *Proceedings of the National Academy of Sciences of the United States of America* **102**, 13909-13914, doi:10.1073/pnas.0506517102 (2005).
- 17 Muraoka, R. S. *et al.* Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. *The Journal of clinical investigation* **109**, 1551-1559, doi:10.1172/JCI15234 (2002).
- 18 Humbert, L., Neel, J. C. & Lebrun, J. J. Targeting TGF-beta signaling in human cancer therapy. *Trends in Cell Mol Biol* **5**, 69-107 (2010).
- 19 Lebrun, J. J. The Dual Role of TGF in Human Cancer: From Tumor Suppression to Cancer Metastasis. *ISRN Molecular Biology* **2012**, 28, doi:10.5402/2012/381428 (2012).
- 20 Xu, J., Lamouille, S. & Derynck, R. TGF-beta-induced epithelial to mesenchymal transition. *Cell research* **19**, 156-172, doi:10.1038/cr.2009.5 (2009).
- 21 Wilson, E. B. *et al.* Human tumour immune evasion via TGF-beta blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. *PloS one* **6**, e22842, doi:10.1371/journal.pone.0022842 (2011).
- 22 Flavell, R. A., Sanjabi, S., Wrzesinski, S. H. & Licona-Limon, P. The polarization of immune cells in the tumour environment by TGFbeta. *Nature reviews. Immunology* **10**, 554-567, doi:10.1038/nri2808 (2010).
- 23 Massague, J. & Gomis, R. R. The logic of TGFbeta signaling. *FEBS letters* **580**, 2811-2820, doi:10.1016/j.febslet.2006.04.033 (2006).
- 24 Shi, Y. & Massague, J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. *Cell* **113**, 685-700 (2003).
- 25 Padua, D. & Massague, J. Roles of TGFbeta in metastasis. *Cell research* **19**, 89-102, doi:10.1038/cr.2008.316 (2009).
- 26 Dai, M. *et al.* A novel function for p21Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFbeta-mediated breast cancer cell migration and invasion. *Breast cancer research : BCR* **14**, R127, doi:10.1186/bcr3322 (2012).
- 27 Makkinje, A. *et al.* AND-34/BCAR3 regulates adhesion-dependent p130Cas serine phosphorylation and breast cancer cell growth pattern. *Cellular signalling* **21**, 1423-1435, doi:10.1016/j.cellsig.2009.05.006 (2009).
- 28 Near, R. I., Zhang, Y., Makkinje, A., Vanden Borre, P. & Lerner, A. AND-34/BCAR3 differs from other NSP homologs in induction of anti-estrogen resistance, cyclin D1 promoter activation and altered breast cancer cell morphology. *Journal of cellular physiology* **212**, 655-665, doi:10.1002/jcp.21059 (2007).
- 29 Ringner, M., Fredlund, E., Hakkinen, J., Borg, A. & Staaf, J. GOBO: gene expression-based outcome for breast cancer online. *PloS one* **6**, e17911, doi:10.1371/journal.pone.0017911 (2011).

- 30 Ma, X. J. *et al.* A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. *Cancer cell* **5**, 607-616, doi:10.1016/j.ccr.2004.05.015 (2004).
- 31 Sims, D. *et al.* ROCK: a breast cancer functional genomics resource. *Breast cancer research and treatment* **124**, 567-572, doi:10.1007/s10549-010-0945-5 (2010).
- 32 Chin, K. *et al.* Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. *Cancer cell* **10**, 529-541, doi:10.1016/j.ccr.2006.10.009 (2006).
- 33 Wendt, M. K., Smith, J. A. & Schiemann, W. P. p130Cas is required for mammary tumor growth and transforming growth factor-beta-mediated metastasis through regulation of Smad2/3 activity. *The Journal of biological chemistry* **284**, 34145-34156, doi:10.1074/jbc.M109.023614 (2009).
- 34 Kim, W. *et al.* The integrin-coupled signaling adaptor p130Cas suppresses Smad3 function in transforming growth factor-beta signaling. *Molecular biology of the cell* **19**, 2135-2146, doi:10.1091/mbc.E07-10-0991 (2008).
- 35 Cai, D. *et al.* AND-34/BCAR3, a GDP exchange factor whose overexpression confers antiestrogen resistance, activates Rac, PAK1, and the cyclin D1 promoter. *Cancer research* **63**, 6802-6808 (2003).
- 36 Flanagan, L., Van Weelden, K., Ammerman, C., Ethier, S. P. & Welsh, J. SUM-159PT cells: a novel estrogen independent human breast cancer model system. *Breast cancer research and treatment* **58**, 193-204 (1999).
- 37 Minn, A. J. *et al.* Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. *The Journal of clinical investigation* **115**, 44-55, doi:10.1172/JCI22320 (2005).
- 38 Kucich, U. *et al.* Signaling events required for transforming growth factor-beta stimulation of connective tissue growth factor expression by cultured human lung fibroblasts. *Archives of biochemistry and biophysics* **395**, 103-112, doi:10.1006/abbi.2001.2571 (2001).
- 39 Dennler, S. *et al.* Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. *The EMBO journal* **17**, 3091-3100, doi:10.1093/emboj/17.11.3091 (1998).
- 40 Humbert, L. & Lebrun, J. J. TGF-beta inhibits human cutaneous melanoma cell migration and invasion through regulation of the plasminogen activator system. *Cellular signalling* **25**, 490-500, doi:10.1016/j.cellsig.2012.10.011 (2013).
- 41 Stopa, M. *et al.* Participation of Smad2, Smad3, and Smad4 in transforming growth factor beta (TGF-beta)-induced activation of Smad7. THE TGF-beta response element of the promoter requires functional Smad binding element and E-box sequences for transcriptional regulation. *The Journal of biological chemistry* **275**, 29308-29317, doi:10.1074/jbc.M003282200 (2000).
- 42 Lamouille, S., Connolly, E., Smyth, J. W., Akhurst, R. J. & Derynck, R. TGF-beta-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. *Journal of cell science* **125**, 1259-1273, doi:10.1242/jcs.095299 (2012).
- 43 Fils-Aime, N. *et al.* MicroRNA-584 and the Protein Phosphatase and Actin Regulator 1 (PHACTR1), a New Signaling Route through Which Transforming Growth Factor-beta Mediates the Migration and Actin Dynamics of Breast Cancer

- Cells. *The Journal of biological chemistry* **288**, 11807-11823, doi:10.1074/jbc.M112.430934 (2013).
- 44 Giampieri, S. *et al.* Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. *Nature cell biology* **11**, 1287-1296, doi:10.1038/ncb1973 (2009).
- 45 Lamouille, S. & Derynck, R. Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. *The Journal of cell biology* **178**, 437-451, doi:10.1083/jcb.200611146 (2007).
- 46 Chhabra, E. S. & Higgs, H. N. The many faces of actin: matching assembly factors with cellular structures. *Nature cell biology* **9**, 1110-1121, doi:10.1038/ncb1007-1110 (2007).
- 47 Safina, A., Ren, M. Q., Vandette, E. & Bakin, A. V. TAK1 is required for TGF-beta 1-mediated regulation of matrix metalloproteinase-9 and metastasis. *Oncogene* **27**, 1198-1207, doi:10.1038/sj.onc.1210768 (2008).
- 48 Lebrun, J. J. The Dual Role of TGF in Human Cancer: From Tumor Suppression to Cancer Metastasis. *ISRN Molecular Biology* **2012**, 1-28 (2012).
- 49 Humbert, L., Neel, J. C. & Lebrun, J. J. Targeting TGF-beta signaling in human cancer therapy. *Trends in Cell Mol Biol* **5**, 69-107 (2010).
- 50 Ho, J. *et al.* The G protein-coupled receptor kinase-2 is a TGFbeta-inducible antagonist of TGFbeta signal transduction. *The EMBO journal* **24**, 3247-3258, doi:10.1038/sj.emboj.7600794 (2005).
- 51 Ho, J., Chen, H. & Lebrun, J. J. Novel dominant negative Smad antagonists to TGFbeta signaling. *Cellular signalling* **19**, 1565-1574, doi:10.1016/j.cellsig.2007.02.001 (2007).

**Figure legends:**

Figure 1. Low BCAR3 expression predict poor prognosis in human breast cancer.

**A and B.** Kaplan-Meier survival curves generated by GOBO gene expression-based outcome tool, showing status of progression free survival (PFS) of a compiled cohort of breast cancer patients who underwent various treatment plans (A) and a compiled cohort of patients who received no systematic treatment (B). Patients were separated by median of signal intensity from an Affymetrix probe targeting BCAR3 (204032\_at) in microarray analysis. Survival data of the high expression group was shown by the red curve, and that of the low expression group was shown by the gray curve. **C and D.** Kaplan-Meier survival curves showing status of distant metastasis free survival (DMFS) of a compiled cohort of breast cancer patients who underwent various treatment plans (C) and a compiled cohort of patients who received no systematic treatment (D). Patients were separated by median of signal intensity from 204032\_at. **E and F.** Kaplan-Meier survival curves showing status of relapse free survival (RFS) of a compiled cohort of breast cancer patients who underwent various treatment plans (E) and a compiled cohort of patients who received no systematic treatment (F). Patients were separated by median (E) or into 5 groups (F). **G.** Dot plot of reading of BCAR3 extracted from the NCBI-GEO dataset GDS-807, which includes microarray readings of gene expression in micro-dissected primary tumors from patients who subsequently received Tamoxifen treatment for 5 years. **H.** Percentage of loss of heterozygosity at BCAR3 alleles in breast tumors with increasing N-stage.

Figure 2. BCAR3 antagonizes Smad activation.

**A.** Total cell lysates from breast cancer cells were subjected for Western blot analysis for expression of BCAR3 and p130Cas. **B.** SCP2 cells were transfected with 50pM BCAR3

siRNA, starved overnight and stimulated with 100pM TGF $\beta$  at 48 hours post-starvation for time periods as indicated. Levels of phospho-Smad3 and BCAR3 were examined by Western blot. **C.** Inducible MCF-7 cells were cultured with or without 1 $\mu$ g/ml doxycycline, starved overnight and stimulated with 100pM TGF $\beta$  at 96 hours post-treatment for time periods as indicated. Levels of phospho-Smad3 and BCAR3 were examined by Western blot. **D.** The stable MCF-7 cells were treated with doxycycline and stimulated as described. Levels of phosphor-Smad3 in nuclear extracts were examined by Western blot. **E.** SUM-159-PT cells were seeded onto glass coverslips, transfected with FLAG-tagged AND-34 (mouse homologue of BCAR3) and starved overnight. Cells were then treated with or without 200pM TGF $\beta$  and subjected for immunofluorescence microscopy and DAPI counter staining. In the merged images, phosphor-Smad3 is shown in red, FLAG-AND-34 is shown in green and cell nucleuses are shown in blue. **F.** phosphor-Smad3 signal in transfected and non-transfected cells were quantified from 5 original LSM images. Error bars show standard errors of the mean. An asterisk indicates a statistical difference between the two groups compared, as determined by unpaired Student's T-test (p<0.05).

Figure 3. BCAR3 antagonizes function of canonical TGF $\beta$  signaling.

**A.** SCP2 cells were co-transfected with 12CAGA-lux luciferase reporter construct, constitutive  $\beta$ -gal construct and 50pM scrambled siRNA control, or a pool of siRNAs targeting BCAR3 (25pM each), or 50pM individual siRNA targeting BCAR3. Cells were starved overnight, stimulated with or without 100pM TGF $\beta$  and subjected for luciferase assays. Luciferase activities were normalized by  $\beta$ -gal activity, and represented as relative luciferase units (RLUs). Error bars show standard errors of the mean of 3

independent experiments. An asterisk indicates a statistical difference, as determined by unpaired Student's T-test ( $p < 0.05$ ). **B.** SUM-159-PT cells were co-transfected with 12CAGA-lux luciferase reporter construct, constitutive  $\beta$ -gal construct and FLAG-AND-34. Luciferase assays were performed as described above. **C.** Inducible MCF-7 cells were cultured with or without doxycycline for 72 hours, starved overnight and stimulated with 100pM TGF $\beta$  for 24 hours. mRNA levels of 3 Smad-dependent genes were examined by real-time PCR. Error bars show SEM of 3 independent experiments. **D.** Inducible MCF-7 cells were cultured with or without doxycycline for 72 hours, starved overnight and stimulated with 100pM TGF $\beta$  for 72 hours. Cell viability was examined by an MTT assay. Error bars show SEM of 3 independent experiments. An asterisk indicates a statistical difference.

Figure 4. Knocking down BCAR3 promotes TGF $\beta$ -induced cell migration.

**A.** SCP2 cells were transfected, scratched and treated as described in Materials and Methods. Real-time migration profiles were compared for mock transfected cells and cells transfected with two different BCAR3 siRNAs. Error bars show standard errors of 4 biological replicates. **B.** representative figures of cell migration from initial scratch (bounded by black regions). Migrated cells were shown by gray zones. **C.** SUM-159-PT cells were transfected with FLAG-AND-34, starved and treated with or without TGF $\beta$ , then subjected for immunofluorescent microscopy. In the merged images, FLAG-AND-34 is shown in green, F-actin is shown in red and cell nucleuses are shown in blue.

Figure 5. Knocking down BCAR3 promotes TGF $\beta$ -induced digestion of gelatin matrix.

**A.** SCP2 cells were transfected with scrambled control siRNA, or BCAR3 siRNA, or mock transfected for 48 hours. Cells were then seeded onto coverslips coated with Alexa488-conjugated gelatin, treated with or without TGF $\beta$  and allowed to digest the

matrix for 36 hours. Representative images show immunofluorescence staining of BCAR3 (white), Actin filaments (red) and gelatin matrix (green). Results represent 3 independent experiments. **B.** The total areas of digestion (pixel count) were quantified for 10 cells transfected with scrambled siRNA, or BCAR3 siRNA, or mock transfected. Cells were from at least 5 LSM images. Error bars showed SEM. **C.** Western blot showing the effect of BCAR3 siRNA. Total cell lysates were collected from the cells from the same pools as the ones seeded onto cover slips.

Figure 6. BCAR3 requires p130Cas to antagonize TGF $\beta$  signaling.









**A.** SCP2 cells were transfected with BCAR3 siRNA, starved overnight and stimulated with TGF $\beta$ . Smad2/3 were immunoprecipitated and levels of p130Cas in the precipitant were examined by Western blot. **B.** SCP2 cells were transfected, starved then stimulated with TGF $\beta$ . Levels of phospho-Smad3 and BCAR3 were examined by Western blot. Signal densities of phospho-Smad3 were normalized with that of total Smad3, and shown below the top panel. **C.** SCP2 cells were transfected with BCAR3 siRNA or p130Cas siRNA or together, starved, stimulated and subjected for Incucyte cell migration assays. Real-time migration profiles were compared for mock transfected cells and cells transfected with BCAR3 siRNA (C), p130Cas siRNA (D) and for cells transfected with p130Cas siRNA and both siRNAs (E). Error bars show standard deviation of the mean for 6 biological replicates. **F.** Relative wound densities at 36h are plotted. Error bars show standard deviation of the mean for 6 biological replicates.







Figure 7. TGF $\beta$  down-regulates BCAR3 in a Smad-dependent manner.

**A.** Breast cancer cells were starved and treated with TGF $\beta$  for 24 hours. Levels of BCAR3 protein expression were examined by Western blot. **B.** BT-549 cells were


transfected with Smad2 siRNA or Smad3 siRNA for 48 hours, starved and treated with TGF $\beta$  for 24 hours. Levels of BCAR3 protein expression were examined by Western blot.

**C.** Model of BCAR3 in mediating a positive feedback loop downstream of TGF $\beta$ /Smad signaling axis.







a




c









b










d












A



B




Figure 1. Knocking down BCAR3 enhances TGF $\beta$ -induced cell invasion through matrigel. A. SCP2 cells were transfected with scrambled siRNA or siRNAs targeting BCAR3 for 72 hours. Cells were then stimulated with or without 100 pM TGF $\beta$ , and subjected for transwell invasion assays for 24 hours. Images of the centers of each transwell chamber were taken. B. Quantification of numbers of invaded cells of a biological triplicate of one representative experiment. Figures represent results of 4 independent experiments.




Figure 2. GRK2 overexpression decreases TGFβ-induced matrix degradation. MDA-MB-231 cells were transfected with FLAG-tagged GRK2 and seeded on coverslips coated with Alexa488-labeled gelatin matrix. Cells were then stimulated with or without TGFβ for 36h, and subjected for immunofluorescence microscopy analysis.

## Appendix C:

### Publications:

4. **Guo J**, Korah J, Rajadurai CV, Dai M, Fils-Aime N, Park M, Ali S, L and Lebrun J-J, Breast Cancer Anti-Estrogen Resistance-3 inhibits TGF $\beta$ /Smad signaling and associates with favorable breast cancer disease outcomes. (under review)
3. Benyoucef Y, Shams A, Liu F, Korah J, **Guo J**, Garic D, Dai M, Yasruel Z, Lebrun JJ and Ali S, A Protective Role for Prolactin in Human Breast Cancer Reveals Novel Function for the RNA-Binding Protein Nudt21 and Paraspeckles in Carcinogenesis. (under review)
2. Dai M, Al-Odaini AA, Fils-Aime N, Villatoro MA, **Guo J**, Arakelian A, Rabbani SA, Ali S, Lebrun JJ. Cyclin D1 cooperates with p21 to regulate TGF $\beta$ -mediated breast cancer cell migration and tumor local invasion. *Breast Cancer Res.* 2013 Jun 20;15(3):R49.
1. Fils-Aime N, Dai M, **Guo J**, Kahramangil B, Neel JC, Lebrun JJ. Micro-RNA-584 and PHACTR1: New Signaling Route Through Which Transforming Growth Factor-Beta Mediates the Migration and Actin Dynamics of Breast Cancer Cells. *Journal of Biological Chemistry* 2013 Epub.

### Posters:

4. **Guo J** and Lebrun JJ, Breast Cancer Anti-Estrogen Resistance 3 Antagonizes Transforming Growth Factor  $\beta$  signaling and is Correlated to Favorable Disease Outcomes in Breast Cancer Patients. AACR Conference on Mechanism of Resistance to Molecular Targeted Therapies, San Diego CA, USA, May 9-12 2012.
3. **Guo J**, Chen H, Ho J and Lebrun JJ, GRK2 Antagonizes the Pro-migratory TGF $\beta$  and Pro-angiogenic Ang II Signaling. AACR Conference on Tumor Microenvironment Complexity, Orlando FL, USA, November 3-6 2011.
2. **Guo J** and Lebrun JJ, BCAR3 promotes interaction between p130Cas and Smad3 to antagonize TGF $\beta$  induced cell invasion in triple negative breast cancer cells. The Biology of Cancer: Microenvironment, Metastasis & Therapeutics, Cold Spring Harbor NY, USA, April 26-20 2011.
1. **Guo J** and Lebrun JJ, BCAR3 is down-regulated by TGF $\beta$  and provides a positive feedback to TGF $\beta$  signaling. McGill University Health Centre Cancer Research Axis Research Day, 2011, Montreal QC, CANADA, Poster 02.